https://sys.8kun.top/file_store/d0cee30011270274cdf26ae762e4a6cedc7cbf36f1ea98c6bd0679e5aa3649f8.pdf/d0cee30011270274cdf26ae762e4a6cedc7cbf36f1ea98c6bd0679e5aa3649f8.jpg?n=39255866172
--January 2021--
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
Leon Calya, Julian D. Drucea, Mike G. Cattona, David A. Jansb, Kylie M. Wagstaffb,∗
a Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australiab Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800, Australia
A B S T R A C T
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h.
Ivermectin therefore warrants further investigation for possible benefits in humans.
See CAP.